Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526526-41-01

Enrollment

Registered

2026-07-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Brief summary

The primary endpoint of this study is the absolute change in serum TTR concentration (mg/dL) from baseline (pre-dose, day 0) to week 4 (day 28 ±5) after initiation of treatment with tafamidis and acoramidis. The pre-specified primary endpoints are the absolute change, with relative (%) change reported as supportive.

Interventions

DRUGBEYONTTRA 356 mg film-coated tablets

DRUGVyndaqel 61 mg soft capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study is the absolute change in serum TTR concentration (mg/dL) from baseline (pre-dose, day 0) to week 4 (day 28 ±5) after initiation of treatment with tafamidis and acoramidis. The pre-specified primary endpoints are the absolute change, with relative (%) change reported as supportive.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 28, 2026